Vitamin K2 compositions for the treatment of drug induced neuropathy
AssigneeSynergia Life Sciences Pvt. Ltd.
InventorsDilip Mehta, Ashok Vaidya, Rama Vaidya, Yogesh Dound, Anselm De Souza
Life of this patent
Estimating the term…
Abstract
The present invention provides the use of vitamin K2 compositions for the treatment of drug-induced neuropathy. More particularly it is related to the use of vitamin K2-7 compositions for the treatment of drug-induced peripheral neuropathy caused by the drugs used for the treatment of multiple myeloma.
Claims13
A method of treating or ameliorating a symptom of cancer drug-induced peripheral neuropathy in a patient suffering from multiple myeloma, the method comprising administering a composition consisting essentially of vitamin K2-7 to the patient, wherein the peripheral neuropathy is caused by the cancer drug used in the treatment of multiple myeloma and the vitamin K2-7 is effective in treating or ameliorating at least one symptom of cancer drug-induced peripheral neuropathy.
A method of preventing the symptoms of cancer drug-induced peripheral neuropathy in a patient suffering from multiple myeloma, the method comprising administering vitamin K2-7 to the patient, wherein the peripheral neuropathy is caused by the cancer drug used in the treatment of multiple myeloma and the vitamin K2-7 is effective in treating or ameliorating at least one symptom of cancer drug-induced peripheral neuropathy.
Dependencies are inferred from the claim text.